Press Releases 2022

Results of the Combined General Meeting on June 21, 2022 All ordinary and extraordinary resolutions presented by the company have been adopted Biophytis announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting. Thanks to the mobilization of shareholders, the CGM could be held on second call with a quorum of more than 23% of the shareholders present or represented. The 26 resolutions presented by the company were approved at a very large majority and were comprising, as an ordinary resolution, the approval of the

Biophytis announced that it is presenting new preclinical efficacy data for its product Sarconeos (BIO101) in SMA (Spinal Muscular Atrophy) at the SMA Cure 2022 conference in Anaheim, California, USA on June 16-19, 2022. This oral presentation given by Dr. Cynthia Bézier and entitled: “COMBINATION OF BIO101 WITH ANTISENSE OLIGONUCLEOTIDE THERAPY DEMONSTRATES SYNERGISTIC BENEFICIAL EFFECTS IN SEVERE SMA-LIKE MICE” demonstrates, in a mouse model of SMA, the synergic effect of Sarconeos (BIO101) with antisense therapy. Stanislas Veillet, CEO of Biophytis, said: “We are very pleased to present this work to the SMA community. These new data highlight the full potential

Convening of Another Combined General Meeting at a Later Date Biophytis informs its shareholders that the combined Annual General Meeting (AGM) held on June 3, 2022 was unable to deliberate, as the required quorum was not reached. The shareholders taking part in the vote owned collectively 23 514 980 shares, or 15.45% of the share capital, and 16.19% of the voting rights. The 20% quorum necessary for holding an ordinary AGM on first call and the 25% quorum necessary for holding an extraordinary General Meeting on first call have not been reached. Therefore, in the absence of the quorum required

Biophytis presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022 Biophytis announces it will present and discuss the results of Sarconeos (BIO101) development program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) to be held virtually and on site in Boston from April 20 to April 22, 2022. ICFSR is the key international scientific event on Frailty and Sarcopenia and is attended by leading researchers, physicians and Biotech/Pharma in this field. On Friday 22, April, Cendrine Tourette, PhD (SARA

Biophytis announces its audited financial results for the year ended December 31, 2021, and provides updates on key operational achievements as well as perspectives for 2022 Success of Nasdaq IPO in February 2021 €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid 2023 Strong growth of operational expenses to €26.8M, mainly reflecting clinical program advancement in COVID-19 (COVA) and in sarcopenia (SARA) Significant milestones reached for COVA and SARA allowing to prepare for future development of the programs Download the Press Release Fullscreen Mode

Biophytis is pleased to announce the appointment of Philippe Rousseau as Chief Financial Officer. He replaces Evelyne Nguyen who is leaving the company to pursue other projects, after having dedicated two years to its development. A strong experience in biotech and listed companies Philippe Rousseau has nearly 25 years of experience in the biotech industry in Europe and the US. Prior to joining Biophytis, Philippe Rousseau was Chief Operating Officer of Pherecydes Pharma, an antibacterial therapeutics development company for two years that he listed on Euronext Growth in 2021. He had also been deputy CEO of the Swiss biomarker and

Biophytis received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program ANVISA (Brazilian Health Authority) approved Biophytis’ Expanded Access Program (EAP) for hospitalized patients with severe COVID-19 and mechanically ventilated in Intensive Care Unit Sarconeos (BIO101) treatment will be given to a maximum of 80 patients mechanically ventilated in Intensive Care Units (ICUs) of Brazilian hospitals In parallel, Sarconeos (BIO101) is being evaluated in a Phase 2-3 study (COVA), in Europe, Latin America, and the US, for the treatment of non-intubated hospitalized patients with severe respiratory manifestations of COVID-19 Download